Protein

IT'S A BUENO KINDA DAY IN ROSENBERG!

Retrieved on: 
Tuesday, August 9, 2022
Taco Bueno, Burger King, Multimedia, SBA, CEO, T-Mobile, Mega 99, Duke of Connaught and Strathearn, Growth, Perales, Mega, Hickory, Nation's Restaurant News, Sun, Ernst & Young, McAlister, Arby's, Mecum Dealmakers, McAlister's Deli, Applebee's, IHOP, Tablet, GNC, Protein, IFA, Ernst & Young Entrepreneur of the Year Award, Digital, Popeyes, Fast food

Adding a brand-new Taco Bueno at 28225 Southwest Fwy, Rosenberg, Texas 77471.

Key Points: 
  • Adding a brand-new Taco Bueno at 28225 Southwest Fwy, Rosenberg, Texas 77471.
  • "The contemporary Tex-Mex flavors, ingredients, and items offered by modernized restaurants and frequent menu changes will continue to drive growth for Taco Bueno in 2022" stated Guillermo Perales, President and CEO of Sun Holdings who owns and operates Taco Bueno.
  • Additionally, Taco Bueno offers a variety of "Big Freakin" options, which are top selling favorites, and twice their regular size.
  • Guillermo Perales, a Dallas restaurant franchise owner (Sun Holdings, Inc.), purchased Taco Bueno in 2019.

Chinova Bioworks Introduces Mycobrio™, a Vegan Fining Agent and Natural Preservative for Alcoholic and Non-Alcoholic Markets

Retrieved on: 
Tuesday, August 9, 2022
FDA, Woman, Organic, Drink, Chitosan, Filtration, PVPP, CEO, Bentonite, GLOBE, Technology, Wine, Society, Environment, Particulates, Review, Gelatin, Food, Bacteria, American Society of Brewing Chemists, Beer, Alcoholism, Tannin, Protein, Food preservation, Bottled water

FREDERICTON, New Brunswick, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Chinova Bioworks (Chinova), a Canadian-based food, and beverage start-up, introduces Mycobrio, a dual functioning mushroom-derived fining agent and natural preservation ingredient formulated explicitly for alcoholic and low/no-alcoholic beverage markets.

Key Points: 
  • FREDERICTON, New Brunswick, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Chinova Bioworks (Chinova), a Canadian-based food, and beverage start-up, introduces Mycobrio, a dual functioning mushroom-derived fining agent and natural preservation ingredient formulated explicitly for alcoholic and low/no-alcoholic beverage markets.
  • It also provides broad spectrum protection against spoilage as a natural antimicrobial agent in wines, beers, ciders, and seltzers.
  • "We are thrilled to have Mycobrio launch into these new alcoholic and low to non-alcoholic beverage categories for Chinova as our newest natural mushroom innovation," said Natasha Dhayagude, CEO and Co-founder of Chinova Bioworks.
  • It is an advanced natural replacement for synthetic and animal-derived fining agents such as isinglass, PVPP, bentonite, and gelatin.

Bluu Seafood presents first cultivated seafood products in Europe - ready to enter regulatory approval process in Asia, the U.S., the UK, and the EU

Retrieved on: 
Tuesday, August 9, 2022
Food technology, Seafood, Protein, Horizon Fuel Cell Technologies, CEO, Research, Environment, Edible, EMB, Biotechnology, Aquaculture, Medical device, EU

The products have reached market readiness and will soon enter the regulatory approval process.

Key Points: 
  • The products have reached market readiness and will soon enter the regulatory approval process.
  • Bluu Seafood targets initial approval and market launch in Singapore by the end of 2023, as the regulatory process there is already well-defined.
  • The food technology company Bluu Seafood is the first company in Europe to specialize in the commercial production of cultivated fish.
  • As a pioneer at the intersection of biotechnology and food technology, Bluu Seafood aims to produce healthy, sustainable, and delicious cultivated fish products.

SentrySciences Introduces ParticleSentryᴬᴵ Software Platform at CO Protein Stability Conference

Retrieved on: 
Tuesday, August 9, 2022
Machine learning, PMT, Electronics, Protein, Technology, CGMP, Patent, CO, DNA, Small business, Confusion, CNN, Software, Human, Solution, Conference, Airport, Medical device

LONGMONT, Colo., Aug. 9, 2022 /PRNewswire-PRWeb/ -- ParticleSentryᴬᴵ is the first software platform offering AI-based, particle image analysis with outlier detection for biopharmaceutical development and manufacturing. The software is based upon five years of testing and development and represents a substantial leap forward in tools available to scientists and engineers for candidate screening and process development. The software recognizes patterns, textural and morphological features that are difficult or impossible for humans to discern and leverage. The analysis allows for creation of a fingerprint that represents the typical heterogenic population of particles in a sample. The fingerprint can be used for quick and easy comparison during candidate testing, like excipient/surfactant screening, stability and stress testing, interface testing, timed storage testing and container/closure and interface testing and qualification.

Key Points: 
  • SentrySciences Inc., a small business headquartered in Longmont Colorado unveiled its revolutionary ParticleSentry software platform at the Colorado Protein Stability Conference in Breckenridge, CO today.
  • LONGMONT, Colo., Aug. 9, 2022 /PRNewswire-PRWeb/ -- ParticleSentry is the first software platform offering AI-based, particle image analysis with outlier detection for biopharmaceutical development and manufacturing.
  • The software recognizes patterns, textural and morphological features that are difficult or impossible for humans to discern and leverage.
  • ParticleSentry is the only software platform delivering focused, tested and versatile AI in the biologics formulation development space.

Protein Expression Global Market Report 2022: Increase in Demand for Biologics to Counter Various Genetic Disorders and Chronic Diseases Propelling Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022
Other Natural Resources, Natural Resources, FDA, Jonathan Rothberg, TOC, World Health Organization, Gene, Application, Industry, Microfluidics, Chemistry World, Hormone, Technology, Cancer, Clinical trial, Research, Blood, Insulin, Pharmacology, Marketing, Cell, Lists of diseases, Vaccine, Conditional sentence, Transport, Safety, Allergen, World, Government, Protein, Time, CFR, Medicine, Health, Pharmaceutical industry, Sphere

The "Protein Expression Global Market Report 2022, By Protein Expression, By End Use, By Product, By Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Protein Expression Global Market Report 2022, By Protein Expression, By End Use, By Product, By Application" report has been added to ResearchAndMarkets.com's offering.
  • Increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market.
  • The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment.
  • Hence the rising demand for biologics is driving the protein expression market.

Indy Medical Group Opens New Medical Weight Loss Clinic in Indianapolis

Retrieved on: 
Tuesday, August 9, 2022
People, FDA, Risk, Eating, Diet, Human, Hunger, B-12, Research, Patient, Pains, Heart rate, ACHES, Overweight, Protein, Weight loss, Health, Metabolism, Dietary supplement, Phentermine, Phentermine

Losing weight is the most important thing people can do to improve their overall health. Being at an optimum weight improves one's chances of having normal blood pressure, fewer aches and pains, and a more efficient digestive system. It also lowers the risk of developing serious diseases. Until now, doctors have been limited to two options; Phentermine, (or Adipex), stimulants that increase the metabolism without curbing hunger--or gastric surgery, a sleeve that restricts the amount of food you can physically eat. This is a serious surgery with a long recovery time and calls for a lifetime of changing one's eating habits.

Key Points: 
  • INDIANAPOLIS, Aug. 9, 2022 /PRNewswire/ -- Indy Medical Group announces the grand opening of a new medical weight loss clinic in Indianapolis, offering the most advanced medical weight loss therapy in over two decades.
  • The practitioner who developed the Indy Weight Loss therapy felt it was time to approach the problem in a new way and find a medical weight loss approach without surgery or serious medications.
  • Indy Medical Group is owned by a weight loss practitioner and a team of specialists trained to work with patients who need to lose weight, but desire to do so without invasive gastric bypass surgery or stimulant-based pharmaceuticals.
  • The Indy Medical Group is now open in Indianapolis and ready to offer safe, effective weight loss with an experienced team, and scheduling an in-person initial consultation is easy, just call 317-427-6050.

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
Death, U.S. Securities and Exchange Commission, Myopathy, Mitochondrial trifunctional protein deficiency, Disorder, Deafness, Gene, CEO, Sudden death, GLOBE, Private Securities Litigation Reform Act, Investment, Clinical trial, Brain, Encephalopathy, Myalgia, Achievement, Tissue, Enzyme, Home After Three Months Away, Life, ATP, Security (finance), PMM, Exercise intolerance, INFORM, Patient, DNA, Liver, A-DNA, Company, Prognosis, Hypoglycemia, Rhabdomyolysis, Lethargy, Program, Severe cognitive impairment, Mitochondrion, Total permanent disability insurance, STRIDE, Research, Protein, Muscle, Metabolism, Nasdaq, Heart, Conference, International Network of Health Promoting Hospitals and Health Services, Lists of diseases, Muscle weakness, Adenosine triphosphate, Pharmaceutical industry, Dietary supplement, Health insurance

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.

Key Points: 
  • IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June30, 2022.
  • The second quarter was a very productive period for the company, highlighted by advancements in both of our mitochondrial disease programs, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • The Company had approximately $127 million in cash, cash equivalents and short-term investments as of June30, 2022.
  • Research and development expenses for the three months ended June30, 2022 were $8.1 million, compared to $6.3 million for the three months ended June30, 2021.

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, GLOBE, Cancer, Investment, Toxicity, Board, Purging disorder, AstraZeneca, Security (finance), Pain, Peripheral neuropathy, Patient, Appetite, Securities Act of 1933, Securities Exchange Act of 1934, Immune system, Inflammation, Industry, FABP5, Lipid, Cannabinoid, Șaeș, CB2, Nature, Board of directors, CB1, Nasdaq, Weight loss, Pharmacokinetics, Anorexia nervosa, Human, Compliance, 8-K, Radiation, Dehydration, Reverse stock split, Anxiety, FABP, Organic acid, RATS, Review, Oxaliplatin, Company, Twitter, Weight gain, Therapy, Protein, Private Securities Litigation Reform Act, Online gambling, Pharmaceutical industry

SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ended June 30, 2022.

Key Points: 
  • The Companys common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, August 10, 2022.
  • For further details, all shareholders are invited to review the 8-K regarding this reverse split filed today, August 9, 2022.
  • Financial Results Ended June 30, 2022
    Operating expenses for the three months ended June 30, 2022, were $2.4 million compared to $2.3 million for the same period in 2021.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Retrieved on: 
Tuesday, August 9, 2022
MSD, CNS, GLOBE, B cell, Discovery, GPR6, Patient, Central nervous system, Therapy, Neurodegeneration, Biology, Neuroscience, Protein, Merck & Co., Pharmaceutical industry, Merck, Cerev Del

BOSTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.

Key Points: 
  • Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration.
  • We believe we are well-positioned to identify novel targets for neurodegenerative diseases and look forward to collaborating with Merck to potentially bring forward transformative therapeutics for patients with Alzheimers disease.
  • We look forward to advancing the discovery program as well as taking advantage of the NETSseq platform to identify new targets with the team at Cerevance.
  • As a result, Cerevances platform can reveal novel therapeutic targets that can be modulated to correct neural circuitry or slow the disease process.

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

Retrieved on: 
Tuesday, August 9, 2022
MDS, U.S. Securities and Exchange Commission, Trial of the century, GLOBE, Cancer, Clinical trial, Security (finance), Blood, Synovial sarcoma, Patient, ARID1B, BRM, ATPase, Development, Choroid, Food, Iris, BRD9, Sarcoma, Food and Drug Administration Amendments Act of 2007, Merck, BAF, Lilly, Ciliary body, Acute leukemia, Ligament, Nasdaq, Chromatin, Uveal melanoma, Forward-looking statement, AML, BRG1, Myelodysplastic syndrome, Cell, Bone marrow, Postcholecystectomy syndrome, Mum, FDA, Acute myeloid leukemia, State Administrative Expenses, Retinoic acid syndrome, Gene expression, Achievement, Company, Twitter, Therapy, Adult, Economics, Protein, LinkedIn, Administration, Medical imaging, Pharmaceutical industry, Cryptocurrency, Vaccine, Dietary supplement, Foghorn, Research

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended June 30, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • Collaboration revenues were $4.5 million for the second quarter of 2022 compared to $0.3 million the second quarter of 2021.
  • Research and Development Expenses.Research and development expenses were $26.0 million for the second quarter of 2022 compared to $18.6 million for the second quarter of 2021.
  • General and Administrative Expenses.General and administrative expenses were $7.7 million for the second quarter of 2022, compared to $4.9 million for the second quarter of 2021.
  • Net Loss.Net loss was $27.3 million for the second quarter of 2022 compared to a net loss of $23.1 million for the second quarter of 2021.